Tissue Regenix Group PLC Directorate Change (8786T)

TIDMTRX

RNS Number : 8786T

Tissue Regenix Group PLC

18 October 2017

[This announcement contains inside information.]

Tissue Regenix Group plc

Directorate Change

Leeds, 18 October 2017 - The Board of Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "The Group") today announces that Antony Odell, Chief Executive Officer (CEO), will be stepping down from his role and position on the Board with immediate effect. The Board will commence a process for appointment of a new CEO. In the interim, John Samuel, Non- Executive Chairman has assumed the role of Executive Chairman.

John Samuel, Executive Chairman Tissue Regenix Group, commented: "The Board of Directors and I would like to thank Antony for his dedication and commitment to Tissue Regenix since he was appointed CEO in 2008. He has been a key member of the executive team. During his tenure the Company has listed on the AIM market, successfully commercialised products in the US and earlier this year completed the transformational acquisition of CellRight, while continuing to pursue additional commercial opportunities. We wish him every success in his future career."

The integration of CellRight continues as planned and current trading remains in line with Board expectations.

For more Information:

 
 Tissue Regenix Group plc                  Tel: 0330 
  Caitlin Pearson Head of Communications    430 3073 
                                            / 07920 
                                            272 441 
----------------------------------------  ----------- 
 Jefferies International Ltd               Tel: 020 
  Simon Hardy / Christopher Binks           7029 8000 
----------------------------------------  ----------- 
 FTI Consulting                            Tel: 0203 
  Brett Pollard / Mo Noonan/ Rob Winder     767 1000 
========================================  =========== 
 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL(R) ') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012, Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017, Tissue Regenix acquired CellRight Technologies(R) , a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAGGGBCUUPMGMM

(END) Dow Jones Newswires

October 18, 2017 02:00 ET (06:00 GMT)